

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS, INC., and  
MERCK SHARP & DOHME CORP.

Petitioners

v.

GENENTECH, INC. AND CITY OF HOPE

Patent Owners

---

U.S. Patent No. 6,331,415

“Methods of Producing Immunoglobulins, Vectors and  
Transformed Host Cells for Use Therein”

---

*Inter Partes* Review No. 2016-00710<sup>1</sup>

**PETITIONER’S REPLY BRIEF**

---

<sup>1</sup> Case IPR2017-00047 has been joined with this proceeding.

**TABLE OF CONTENTS**

	<b><u>Page</u></b>
I. INTRODUCTION: GENENTECH’S “UNCERTAINTY” AND “PREVAILING MINDSET” ARGUMENTS ARE CONTRARY TO THE CONTEMPORANEOUS EVIDENCE .....	1
II. GROUND I: GENENTECH’S ARGUMENTS REGARDING THE COMBINATION OF BUJARD WITH RIGGS & ITAKURA SHOULD BE REJECTED .....	3
A. Genentech’s Reading of Bujard Is Inappropriately Narrow .....	3
1. Bujard Teaches A Method for Producing Antibodies .....	4
2. Bujard Teaches the Use of Co-Expression of Multiple Genes of Interest in a Single Host Cell.....	7
(a) Genentech’s Interpretation of “Multimer” Is Wrong .....	8
(b) Genentech’s Interpretation of “One or More Structural Genes” Is Wrong.....	9
(c) The Use of Multiple Stop Codons Teaches The Inclusion of Multiple Genes of Interest.....	10
3. Bujard Teaches the <i>In Vivo</i> Assembly of a Multimeric Protein Encoded by More than One Gene in a Single Host Cell .....	10
B. It would have been obvious to combine Bujard with Riggs & Itakura.....	11
1. A POSA Would Have Been Motivated to Combine Bujard with Riggs & Itakura.....	11
2. The Board Correctly Found That Riggs & Itakura Does Not Teach Away .....	13
3. A POSA Would Have Had a Reasonable Expectation of Success in Combining Bujard with Riggs & Itakura.....	13
III. GROUND 2: GENENTECH’S ARGUMENTS REGARDING THE COMBINATION OF BUJARD WITH SOUTHERN SHOULD BE REJECTED .....	15
A. Southern Discloses a Two-Vector Approach to Express Multiple Proteins of Interest in a Single Host Cell .....	16

B.	A POSA Would Have Been Motivated to Combine Bujard with Southern.....	18
C.	A POSA Would Have Had a Reasonable Expectation of Success in Combining Bujard with Southern.....	19
D.	Genentech’s Arguments That Southern Cannot Invalidate Claims 1, 2, and 33 Are Wrong.....	20
IV.	GENENTECH’S SECONDARY CONSIDERATIONS EVIDENCE SHOULD BE GIVEN NO WEIGHT .....	21
A.	Genentech Is Not Entitled to a Presumption of Nexus .....	21
B.	Genentech Fails to Establish a Nexus Between its Licensing Program and the Challenged Claims.....	22
C.	Genentech Fails to Establish a Nexus Between Any Alleged Commercial Success and the Challenged Claims .....	23
D.	There Was No Skepticism of Those Skilled in the Art.....	23

## TABLE OF AUTHORITIES

<u>Cases</u>	<u>Page</u>
<i>Apple, Inc. v. Ameranth, Inc.</i> CBM2015-00080 (Aug. 26, 2016).....	21
<i>In re Antor Media Corp.</i> , 689 F.3d 1282 (Fed. Cir. 2012) .....	22
<i>AstraZeneca LP v. Breath Ltd.</i> , 603 F. App'x 999 (Fed. Cir. 2015) .....	14
<i>Biomerieux, Inc. v. Patent Inst. for Envtl. Health Inc.</i> , Appeal 2014-007983, 2015 WL 294327 (PTAB Jan. 20, 2015).....	23
<i>In re Bode</i> , 550 F.2d 656 (C.C.P.A. 1977) .....	5
<i>In re Carlson</i> , 983 F.2d 1032 (1992).....	4
<i>Demaco Corp. v. F. Von Langsdorff Licensing Ltd.</i> , 851 F.2d 1387 (Fed. Cir. 1988) .....	21
<i>Eolas Techs. Inc. v. Microsoft Corp.</i> , 399 F.3d 1325 (Fed. Cir. 2005) .....	4
<i>In re Ethicon, Inc.</i> , 844 F.3d 1344 (Fed. Cir. 2017) .....	5
<i>Galderma Labs., L.P. v. Tolmar</i> , 737 F.3d 731 (Fed. Cir. 2013) .....	13
<i>GrafTech Int'l Holdings, Inc. v. Laird Techs. Inc.</i> , 652 Fed. App'x 973 (Fed. Cir. June 17, 2016).....	22
<i>KSR Int'l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007).....	12, 14
<i>Pfizer, Inc. v. Apotex, Inc.</i> , 480 F.3d 1348 (Fed. Cir. 2007) .....	13
<i>Therasense, Inc. v. Becton, Dickinson &amp; Co.</i> , 593 F.3d 1289 (Fed. Cir. 2010) .....	21, 22

## EXHIBIT LIST

<u>Exhibit No.</u>	<u>Description</u>	<u>Abbreviation</u>
<b>1001</b>	U.S. Patent No. 6,331,415	The '415 patent
<b>1002</b>	U.S. Patent No. 4,495,280	Bujard, or the Bujard Patent
<b>1003</b>	Riggs and Itakura, <i>Synthetic DNA and Medicine</i> , American Journal of Human Genetics, 31:531-538 (1979)	Riggs & Itakura
<b>1004</b>	Southern and Berg, <i>Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter</i> , Journal of Molecular and Applied Genetics, 1:327341 (1982)	Southern
<b>1005</b>	U.S. Patent No. 4,237,224	Cohen & Boyer, or the Cohen & Boyer patent
<b>1006</b>	Declaration of Jefferson Foote, Ph.D., in Support of Sanofi And Regeneron's Petition for Inter Partes Review of U.S. Patent No. 6,331,415	Foote Decl.
<b>1007</b>	U.S. Patent No. 4,816,657	The Cabilly I patent
<b>1008</b>	'415 patent reexamination, Office Action dated 2/16/07	Office Action (2/16/07)
<b>1009</b>	'415 patent reexamination, Owners' Resp. dated 11/25/05	Owners' Resp. (11/25/05)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.